Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app replace hospital rehab for lung disease?

NCT ID NCT07780201

Disease control Sponsor: University Hospitals, Leicester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether a digital rehabilitation programme called I-IMPACT can be a practical alternative to traditional centre-based pulmonary rehabilitation for adults with interstitial lung disease (ILD). The study will compare the two approaches, focusing on feasibility—such as recruitment, adherence, and acceptability—rather than just clinical outcomes. Participants will be randomly assigned to either the digital programme or usual care, and researchers will also gather feedback from patients and healthcare professionals. If the digital approach proves feasible, it could offer a more flexible and accessible option for managing ILD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
I-IMPACT, a digital self-management rehabilitation programme
What this could lead to
If successful, this could offer a convenient home-based alternative to traditional pulmonary rehabilitation, potentially improving access for people with interstitial lung disease.
What could go wrong
This is a small feasibility study, so it may not provide definitive evidence of effectiveness. Digital programmes may not suit everyone, and adherence could be a challenge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patient participants: * Age: ≥ 18 years * Consent: willing and able to provide informed consent to participate in the study * Diagnosis: physician-confirmed diagnosis of ILD of any subtype * Clinically stable: no ILD exacerbation or respiratory-related hospitalisation in the preceding four weeks. * Digital access: able to access and use the internet and an internet-enabled device to engage with I-IMPACT. * Language: able to read and write in English to complete the programme and study assessments. * Randomisation: willing to be randomised to either arm Staff participants: * Consent: willing and able to provide informed consent to participate in the study * Professional role: a qualified healthcare professional involved in delivering ILD care and/or pulmonary rehabilitation (PR) at the UHL NHS Trust or another healthcare organisation. * Employment duration (UHL staff only): must have been employed by the UHL NHS Trust for at least two years. * Language: able to read and write in English to complete the acceptability questionnaire and optional interview. Exclusion Criteria: Patient participants: * Recent or concurrent PR: concurrent enrollment or recent completion of a PR programme within the 12-months preceding enrollment. * Contraindications to exercise: presenting with exercise-related contraindications (unstable cardiovascular disease; hypertension, etc., a full list is described by the American College of Sports Medicine and is routinely deployed).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung disease (ILD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease (ILD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.